Geographic Atrophy (GA) Market: Key Players and Strategies 2024-2032
The Geographic Atrophy (GA) Market Size was valued at USD 2.26 billion in 2023 and is expected to reach USD 13.77 billion by 2031, growing at a compound annual growth rate (CAGR) of 25.3% during the forecast period. Rising global prevalence of age-related macular degeneration (AMD), coupled with advancements in diagnostic technologies and emerging therapeutics, is driving strong momentum in the Geographic Atrophy (GA) market Size.
Geographic Atrophy is a chronic, progressive form of dry age-related macular degeneration that leads to the gradual loss of vision. The increasing elderly population, greater awareness about early diagnosis, and growing investment in ophthalmic research have been key factors contributing to the market expansion. As pharmaceutical companies focus on developing innovative treatment options, the demand for effective GA management solutions continues to grow.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/2480
Key Players
- Iveric Bio (Zimura (avacincaptad pegol))
- Alkeus Pharmaceuticals, Inc. (ALK-001)
- Apellis Pharmaceuticals, Inc. (APL-2)
- Genentech, Inc. (OpRegen)
- Stealth BioTherapeutics (Elamipretide)
- Allegro Ophthalmics, LLC (Risuteganib)
- Gyroscope Therapeutics Limited (GT005)
- Regenerative Patch Technologies, LLC (CPCB-RPE1)
- NGM Biopharmaceuticals Inc. (NGM621)
- Novartis (PPY988)
- Perceive Biotherapeutics, Inc. (VOY-101)
- Annexon, Inc. (ANX007)
- Aviceda Therapeutics (AVD-104)
- Ionis Pharmaceuticals, Inc. (IONIS-FB-LRx)
- Astellas Pharma Inc. (ASP7317), and others.
Key Points:
- The market is projected to grow at a CAGR of 25.3% from 2023 to 2031.
- Rising incidence of AMD among the aging population is a major growth driver.
- Technological advances in imaging and diagnostic tools are enhancing early detection.
- Strategic collaborations and R&D investments are fostering innovation.
- North America currently holds the largest market share due to advanced healthcare infrastructure.
- Asia-Pacific is expected to witness the fastest growth due to rising healthcare spending and awareness.
Future Scope:
With recent FDA approvals and promising clinical trials underway, the GA market is poised for significant breakthroughs. Emerging therapies, including complement inhibitors and gene therapies, offer new hope for patients and open untapped market opportunities for pharmaceutical firms. Digital health integration and AI-driven diagnostic tools are also anticipated to enhance patient monitoring and personalized treatment plans in the near future.
Conclusion:
The Geographic Atrophy (GA) market is on a transformative path, driven by medical innovation, demographic trends, and improved healthcare access. As the industry shifts toward targeted therapies and precision medicine, stakeholders across the value chain are likely to witness robust growth, making GA one of the most dynamic segments within the ophthalmology market landscape.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
Comments
0 comment